LivaNova

03 2021 FINANCIAL RESULTS


Financial Summary¹

Net Sales	\$253M
Adjusted Gross Margin	71%
Adjusted Operating Margin	19%
Adjusted Diluted EPS	\$0.68

"Our third-quarter performance demonstrates continued focus on execution across all regions in our key product lines amidst lingering COVID-19-related headwinds. We are encouraged by our sales growth year over year and compared to 2019, excluding the impact of Heart Valves. In addition, we saw improvements in margins and cash flow generation. We also strengthened our financial flexibility with the completion of an equity offering during the quarter, which allowed us to retire the \$450 million term loan and enter into a new \$125 million revolver." - Damien McDonald, CEO of LivaNova



Net Sales Summary 2, 3



2021 Guidance ⁴		Highlights			
	Guidance, Aug. 16, 2021	Guidance, Nov. 3, 2021		>20%	
Net Sales	5-10%	8-11%	Sales Growth,	Organic Growth in	
Adjusted Diluted EPS	\$1.75-2.05	\$2.00-2.10	Margin Expansion and FCF Generation	Advanced Circulatory Support	
Adjusted Free Cash Flow (FCF)	\$50-70M	\$55-75M	sequentially and over previous year ⁽⁵⁾	driven by LifeSPARC [®] launch	

2021 Strategic Priorities

Core Growth

- · Expand the go-to-market initiative for U.S. Epilepsy
- ACS growth of over 30% in 2021

Pipeline Execution

- · Achieve key study milestones in:
 - RECOVER and ANTHEM HFrEF
- Advance next-generation HLM

Operational Excellence

- · Expand operating margin through cost discipline
- Drive improvement in free cash flow generation

Definitions:

- ACS: Advanced Circulatory Support
- HF: Heart Failure
- HLM: Heart-Lung Machine

1) Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciliation of GAAP to non-GAAP Financial Measures" contained on the back of this document. All EPS measures in this document refer to diluted EPS from continuing 1) Adjusted financial measures are non-GAAP measures and exclude specified terms as described and reconciled in the "Reconciliation of GAAP Financial Measures" contained on the back of this document. All ESP measures in this document refet to diluted EPS from continuing operations. 2) Unless otherwise noted, all sales growth rates in this document refet constant-currency grien growth, which effects of foreign currency fluctuations. Constant-currency growth, and APP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking not sales growth avoid the include the factor of foreign currency fluctuations. Constant-currency sales and excludes the following one-fine extraordinary adjustments: 3T litigation payments and a tax stimulus benefit. Forward-looking non-GAAP adjusted diluted earnings per share guidance exclude the ritems such as, but not limited to, stock-based compensation costs, changes in fair value of contingent constant-currency excludes are subject to uncertainty adjustments; and exclude the included and adjusted diluted earnings per share reserved. How were, non-GAAP financial adjustments on a forward-looking non-GAAP adjusted diluted earnings per share reserved. How were, non-GAAP financial adjustments on a forward-looking non-GAAP adjusted diluted earnings per share reserved. How were, non-GAAP financial adjustments on a forward-looking non-GAAP adjusted diluted earnings per share reserved. How were, non-GAAP financial adjustments is are subject to uncertainty adjusted diluted earnings per share reserved. How were, non-GAAP financial adjustments on a forward-looking non-GAAP adjusted diluted earnings per share reservel-low were, non-GAAP financial adjustments on a forward-looking non-GAAP adjusted diluted earnings per share reservel-low. How were, non-GAAP financial adjustments on a forward-looking non-GAAP adjusted diluted earnings per share reservele-share, non-GAAP financial adjustments on a forward-look

Core Growth

Quality in everything we do

> Operational Excellence

Pipeline

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES – UNAUDITED

Three Months Ended September 30, 2021

	GAAP Financial Measures	Depreciation and Amortization Expenses (A)	Financing Transactions (B)	Certain Legal, Contingent Consideration and Other (C)	Stock-based Compensation Costs (D)	Certain Tax Adjustments (E)	Certain Interest Adjustments (F)	Heart Valves (G)	Adjusted Financial Measures
Gross Margin %	67.2%	1.6%	-	1.8%	0.1%		-		70.7%
Operating Margin %	7.1%	2.8%		4.6%	4.4%			0.1%	18.9%
Diluted EPS – Continuing Operations	(\$0.82)	\$0.12	\$0.88	\$0.20	\$0.21	(\$0.02)	\$0.08	\$0.02	\$0.68

Three Months Ended September 30, 2020

	GAAP Financial Measures	Depreciation and Amortization Expenses (A)	Financing Transactions (B)	Certain Legal, Contingent Consideration and Other (C)	Stock-based Compensation Costs (D)	Certain Tax Adjustments (E)	Certain Interest Adjustments (F)	Product Remediation Expenses (H)	Restructuring Expenses (I)	Merger and Integration Expenses (J)	Adjusted Financial Measures
Gross Margin %	61.5%	2.2%		2.2%	0.2%			0.5%			66.5%
Operating Margin %	(3.1)%	4.7%		7.8%	3.3%	-		0.5%	(0.1)%	0.5%	13.4%
Diluted EPS – Continuing Operations	(\$0.30)	\$0.20	(\$0.10)	\$0.38	\$0.15	(\$0.05)	\$0.07	\$0.02	(\$0.01)	\$0.02	\$0.38

GAAP results include:

(A) Includes depreciation and amortization associated with purchase price accounting

(B) Costs associated with the June 2020 financing transactions, including the mark-to-market adjustment for the exchangeable option feature and capped call derivatives. Three-month period ended September 30, 2021 also includes loss on debt extinguishment.

(C) 3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements, other matters and remeasurement of contingent consideration related to acquisitions

(D) Non-cash expenses associated with stock-based compensation costs

(E) Primarily relates to discrete tax items. Three-month period ended September 30, 2020 also includes the tax impact of intercompany transactions.

(F) Primarily relates to non-cash interest expense on the Senior Secured Term Loan and Cash Exchangeable Senior Notes. Three-month period ended September 30, 2020 also includes non-cash interest expense related to intellectual property migration and interest reversed upon the settlement of a tax litigation matter.

(G) Loss associated with the sale of Heart Valves

(H) Costs related to the 3T Heater-Cooler remediation plan

- (I) Restructuring expenses related to organizational changes
- (J) Merger and integration expenses related to our legacy companies and recent acquisitions
- * Numbers may not add precisely due to rounding.

NET SALES: COMPARISON OF ACTUAL RESULTS TO CONSTANT CURRENCY – UNAUDITED ⁽¹⁾ (U.S. dollars in millions)</sup>

	Three Months End	ed September 30,	W Oberida et Astual Ourrenau Datas	% Change at Constant-Currency Rates		
Business	2021	2020	% Change at Actual Currency Rates	A change at constant-currency rates		
Cardiovascular	\$138.6	\$140.9	(1.6)%	(1.9)%		
Neuromodulation	113.3	98.4	15.1%	14.6%		
Other	1.3	0.8	62.4%	61.2%		
Total Net Sales	\$253.2	\$240.1	5.5%	5.0%		

	Three Months End	ed September 30,	W Oberros et Astual Ourrensu Bates	% Change at Constant-Currency Rates		
Region	2021	2020	% Change at Actual Currency Rates	70 Ghange at Constant-Currency Rates		
US	\$143.8	\$128.9	11.6%	11.6%		
Europe	45.7	48.5	(5.8)%	(7.5)%		
Rest of World	63.7	62.7	1.6%	1.3%		
Total Net Sales	\$253.2	\$240.1	5.5%	5.0%		

(1) Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period. The sales results presented are unaudited.

Numbers may not add or recalculate precisely due to rounding.